[{"id":"219d1e0e-b56c-4bab-85c7-f221ec0d5b47","acronym":"","url":"https://clinicaltrials.gov/study/NCT05252390","created_at":"2022-02-23T19:55:04.757Z","updated_at":"2024-07-02T16:35:00.496Z","phase":"Phase 1/2","brief_title":"NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05252390","lead_sponsor":"Nuvation Bio Inc.","biomarkers":" BRCA","pipe":" | ","alterations":" HRD • BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Xtandi (enzalutamide) • NUV-868"],"overall_status":"Recruiting","enrollment":" Enrollment 657","initiation":"Initiation: 03/29/2022","start_date":" 03/29/2022","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-05-29"}]